Menu Search
Equities

Level Bio AB (publ)

4MB:DEU

Level Bio AB (publ)

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Level Bio AB (publ), formerly Alphahelix Molecular Diagnostics publ AB, is a Sweden-based company active in medical technology. The Company conducts research and development of patented technology that enables the identification of viruses and bacteria. Level Bio is the parent company in the group, with operations in the subsidiaries CyberGene and Techtum Lab. CyberGene develops and manufactures diagnostic kits for the clinical market. Techtum Lab is a reputable distributor and full-service partner to molecular biology labs in the Nordics. The products are sold under several brands and via its own distributors, mainly to laboratories and research institutes. The biggest activity is found within the Nordic market. The head office is in Nacka.

  • Revenue in SEK (TTM)--
  • Net income in SEK--
  • Incorporated1998
  • Employees13.00
  • Location
    Level Bio AB (publ)Fannys Vag 5NACKA 131 54SwedenSWE
  • Phone+46 18120701
  • Websitehttps://levelbio.se/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		LEVBIO:NGM since
announced		Transaction
value
Life Genomics ABDeal withdrawn31 May 202331 May 2023Deal withdrawn-46.67%3.66m
Data delayed at least 15 minutes, as of May 28 2024.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.